Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838755 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT05838755 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 147 participants.
The verdict
NCT05838755, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.
Interventions
- DRUG Placebo
- DRUG GSK3858279
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05838755
The ClinicalTrials.gov registry entry for NCT05838755 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05838755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05838755 about?
NCT05838755 is a clinical study titled "A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain". This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to ...
What is the current status of trial NCT05838755?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2023-09-20. Estimated completion is 2025-02-17.
What interventions are being tested in trial NCT05838755?
The interventions under investigation include: Placebo (DRUG), GSK3858279 (DRUG).
Who is sponsoring clinical trial NCT05838755?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.